BPRDPO-56 by Molecular Targeting Technologies for Solid Tumo

BPRDPO-56 is under clinical development by Molecular Targeting Technologies and currently in Phase I for Solid Tumor.

Related Keywords

Pennsylvania , United States , West Chester , , Globaldata Pharmaceutical Intelligence Center , Molecular Targeting Technologies , Solid Tumor , Phase Transition Success Rate Model , Targeting Technologies , Pharmaceutical Intelligence ,